2/2: UHCOP-DLDCCC alliance: Cancer drug discovery/development and education

2/2：UHCOP-DLDCCC 联盟：癌症药物发现/开发和教育

• 批准号: 9789842
• 负责人: Diana S-L. Chow
• 金额: $ 25.03万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9789842
• 关键词: Address; Administrator; Advisory Committees; African American; Antineoplastic Agents; Applications Grants; Awareness; Cancer Biology; Cancer Burden; Cancer Center Planning Grant; Cancer Survivorship; Cessation of life; Chemistry; Cities; Clinical; Clinical Trials; Communities; Complement; Comprehensive Cancer Center; Core Facility; DNA; Data; Development; Diagnosis; Education; Education Projects; Education and Outreach; Educational Curriculum; Ensure; Ethnic group; Exhibits; Funding; Future; Genome; Goals; Grant; Health; Hispanic Americans; In Vitro; Incidence; Infrastructure; Institution; Joints; Lead; Libraries; Malignant Neoplasms; Medical center; Medicine; Mentors; Methylation; Mus; Patients; Peptoids; Pharmacologic Substance; Pharmacy Faculty; Pharmacy facility; Pilot Projects; Population; Population Group; Prevalence; Primary carcinoma of the liver cells; Program Development; Proteins; Records; Research; Research Personnel; Research Project Grants; Resistance; Students; Technology; Texas; Time; Training; Training and Education; Transcription Coactivator; United States; United States National Institutes of Health; Universities; anticancer research; cancer health disparity; cancer therapy; career; college; design; drug development; drug discovery; education research; experience; genome wide methylation; graduate student; health disparity; hormone therapy; in vivo evaluation; inhibitor/antagonist; innovation; lectures; malignant breast neoplasm; meetings; member; methylation pattern; multidisciplinary; new technology; novel; outreach; prognostic; programs; research and development; small molecule inhibitor; success; training opportunity; treatment trial; undergraduate research; undergraduate student

SUMMARY OF P20 APPLICATION Our University of Houston College of Pharmacy (UHCOP)-Dan L. Duncan Comprehensive Cancer Center (DLDCCC) alliance will develop the infrastructure for a joint drug discovery/development research program to treat cancers with a health disparity and a joint Cancer Research Education Program (CREP). This alliance is built on complementary expertise in cutting-edge cancer drug discovery technologies at DLDCCC/Baylor College of Medicine (BCM) and in development of cancer drugs at UHCOP. The UHCOP is a constituent of the University of Houston (UH), which is an institution serving underserved health disparity populations (ISUPS). UHCOP faculty members bring a unique perspective from an ISUPS, which is complemented by a wealth of pharmaceutical discovery and development experience, existing programs for undergraduate research, and clinical expertise in working with underserved communities. The DLDCCC, an NCI-designated Comprehensive Cancer Center, contributes prominent experience and perspective in current cancer treatments and clinical trials, cutting edge drug discovery technologies and expertise, cancer research core facilities, and existing undergraduate and graduate training and education programs, including those for patients with cancer health disparities. UHCOP and BCM are member institutions of the Texas Medical Center, the largest medical center in the world. The UHCOP/DLDCCC alliance will be led by an Administrative Core, comprised of senior and experienced investigators in drug discovery/development and cancer biology research. The Internal Advisory Committee (IAC), composed of experienced and senior cancer research and/or education experts, will guide the alliance to ensure the successful completion of the proposed goals. The Administrative Core and IAC will serve as mentors to Co-Leaders of pilot projects, the CREP, and participating early-stage investigators and underrepresented (UR) trainees. We have selected two co-developed and collaborative Pilot Projects, from a total of six, to demonstrate the feasibility of the joint infrastructure for drug discovery/development research investigating cancers with health disparities. These pilot projects have strong potential to launch bi-institutional, NIH-funded cancer drug discovery/development programs and create state-of-the-art cancer research training opportunities. We have co-developed a synergistic CREP that will encourage and prepare UR trainees to enter careers in cancer research. Through research experiences, cancer-specific curricula, and education outreach efforts to the UR trainees, the CREP will provide a platform for long-term sustained efforts for enlarging the pipeline of UR trainees in cancer research. The ultimate goal of the UHCOP-DLDCCC alliance will be to support a multiplier effect by developing joint infrastructure in drug discovery/development, education, and novel cancer technologies to target the unmet need of tackling cancer health disparities and generate preliminary data for successful subsequent NCI R-type grant funding.

P20申请的摘要 我们的休斯顿大学药学院（UHCOP）-Dan L. Duncan综合癌症中心 （DLDCCC）联盟将开发联合药物发现/开发研究计划的基础设施 治疗健康差异和联合癌症研究教育计划（CREP）的癌症。这个联盟是 建立在DLDCCC/Baylor的尖端癌症药物发现技术方面的补充专业知识上 医学院（BCM）和在UHCOP开发癌症药物。 UHCOP是 休斯敦大学（UH），该机构为服务不足的健康差异人群（ISUP）提供服务。 UHCOP教师带来了ISUP的独特观点，这是由大量的财富补充 药物发现和发展经验，现有的本科研究计划以及 与服务不足的社区合作的临床专业知识。 DLDCCC，NCI指定的综合 癌症中心，在当前的癌症治疗和临床方面贡献了重要的经验和观点 试验，尖端药物发现技术和专业知识，癌症研究核心设施以及现有 本科和研究生培训和教育计划，包括针对癌症健康患者 差异。 UHCOP和BCM是最大的医疗中心得克萨斯医疗中心的会员机构 在世界上。 UHCOP/DLDCCC联盟将由由高级和 经验丰富的药物发现/开发与癌症生物学研究的研究者。内部咨询 由经验丰富和高级癌症研究和/或教育专家组成的委员会（IAC）将指导 联盟，以确保成功完成拟议的目标。行政核心和IAC将 作为试点项目，CREP和参与早期调查人员的共同领导者的导师 代表性不足（UR）学员。我们从一个共同开发和协作的飞行员项目中选择了 总共六个，以证明药物发现/开发研究的联合基础设施的可行性 调查具有健康差异的癌症。这些试点项目具有发射双制度的强大潜力， NIH资助的癌症药物发现/开发计划并创建最先进的癌症研究培训 机会。我们共同开发了一个协同的CREP，它将鼓励和准备您的受训者进入 癌症研究的职业。通过研究经验，特定于癌症的课程和教育外展 向您的学员努力，CREP将为长期持续努力提供一个平台，以扩大 UR学员在癌症研究中的管道。 UHCOP-DLDCCC联盟的最终目标是 通过在药物发现/开发，教育和 新颖的癌症技术针对解决癌症健康差异并产生的未满足的需求 成功随后的NCI R型赠款资金的初步数据。